Lot certificates published
Plain, secure packaging
Purely Peptides
Research Catalog

Compound monograph

Survodutide

Survodutide is a lipidated synthetic peptide agonist at both the GLP-1 receptor and the glucagon receptor, built on a modified glucagon-family backbone with a branched side-chain linker.

Published: 2026-09-13Last updated: 2026-10-15Literature/identifier verification: 2026-09-13
Also known asBI 456906BI-456906BI 456906
Multi-receptor incretin analogs

01

Identity & nomenclature

Survodutide is a lipidated synthetic peptide agonist at both the GLP-1 receptor and the glucagon receptor, built on a modified glucagon-family backbone with a branched side-chain linker.

A registry representation showing the main chain and the linker as separate sequences does not mean the substance is a mixture of two peptides. Survodutide and mazdutide are both GLP-1/glucagon dual agonists and are not interchangeable: they differ in main-chain sequence, nonstandard residue, conjugation position, linker and lipid. Shared receptor pharmacology is a classification, not chemical equivalence.

Declared aliases and development codes: BI 456906, BI-456906, BI 456906.

02

Molecular properties

Molecular formulaC192H289N47O61
Molecular mass4231.63 Da
CAS Registry Number2805997-46-8
PubChem CID171378821
UNII2ALA66NS64
Three-letter sequenceHis–Ac4c–Gln–Gly–Thr–Phe–Thr–Ser–Asp–Tyr–Ser–Lys–Tyr–Leu–Asp–Glu–Arg–Ala–Ala–Lys–Asp–Phe–Ile–Lys–Trp–Leu–Glu–Ser–Ala
Terminal groupsFree N-terminus; C-terminal amide at Ala29

Position 2 is Ac4c, 1-aminocyclobutane-1-carboxylic acid. It is NOT Aib. The two differ by one carbon, 12.0000 Da exactly, and substituting one for the other imports the chemistry of a different peptide. The 29-residue main chain is also not the whole molecule: a gamma-Glu-Gly-Ser-Gly-Ser-Gly-Gly linker is amidated to the Lys24 side chain and carries a C18 dicarboxylic fatty acid.

03

Structural characteristics

The 29-residue main chain is glucagon-derived. Position 2 carries 1-aminocyclobutane-1-carboxylic acid (Ac4c), not the alpha-aminoisobutyric acid found in several other analogs here, with further substitutions along the chain, a C-terminal amide, and a branched linker from the lysine 24 side chain to a C18 fatty diacid. The related glucagon entry identifies scaffold ancestry; GLP-1(7-36) amide is a native receptor comparator. GLP-1 receptor activity is engineered and does not indicate GLP-1 ancestry. Zimmermann et al. (PMID 36356832) describe survodutide as made by introducing modifications into the human glucagon sequence, whereas a review by Cabri et al. (PMID 34195230) calls it an oxyntomodulin analogue; this record follows the design paper. Functional potencies at the two receptors have been reported in a single cAMP assay system containing bovine serum albumin. Those are assay-specific functional values, not equilibrium binding affinities, and protein content in the assay materially affects the apparent profile. The published values should not be restated as an invariant balanced ratio, and a full-versus-partial agonist classification independent of assay conditions is not established.

  • Ac4c at position 2
  • Lys24 side-chain branched linker
  • C18 dicarboxylic fatty-acid acylation

Terminal features: Free N-terminus, C-terminal amide at Ala29.

04

Molecular targets & mechanisms

Glucagon-like peptide-1 receptor

GLP-1R

GLP-1R is a class B G-protein-coupled receptor. The cited structural and pharmacology records characterize semaglutide and retatrutide as peptide agonists at this receptor.

Glucagon receptor

GCGR

GCGR is a class B G-protein-coupled receptor. Retatrutide's LY3437943 discovery record characterizes a molecular agonist relationship at GCGR alongside GIPR and GLP-1R.

05

Analytical considerations

Confirmation requires the intact mass, the 29-residue main chain, Ac4c at position 2, conjugation at Lys24, the complete linker, the C18 diacid and the Ala29 amide. Tandem MS coverage is needed on both sides of Lys24; a backbone-only database match does not characterise the branch. A GLP-1R and GCGR cAMP panel confirms a functional profile, not molecular identity, because other dual agonists produce similar responses. For bulk powder, counterion, water and peptide content are separate measurements from chromatographic area purity.

Disagreements and mix-ups

Points where sources disagree about this compound's identity, or where a name or form is easily confused with another, as noted in this record. The discrepancy register quotes the passage for each one.

What the studies reported

Each finding describes one cited study in its stated model. These observations are specific to that study and do not establish effects in other settings.

Cell and tissue studies

  • CHO-K1 cells expressing human GLP-1R or GCGR

    Zimmermann et al. measured functional EC50 values of 0.33 nM at human GLP-1R and 0.52 nM at human GCGR for BI 456906 in CHO-K1 cell assays.

    Reference [1]

  • Primary mouse, rat, cynomolgus monkey and human hepatocytes

    Zimmermann et al. observed activation of endogenous GCGR by BI 456906 in primary mouse, rat, cynomolgus monkey and human hepatocyte cAMP assays and inhibition of glycogen synthesis in primary rat hepatocytes.

    Reference [1]

Animal studies

  • Male C57BL/6NRj mouse and male beagle dog pharmacokinetic models

    Zimmermann et al. reported mean residence times of 44 hours in male C57BL/6NRj mice and 140 hours in male beagle dogs for BI 456906, with times to maximum concentration of 7 and 51 hours, respectively.

    Reference [1]

  • Lean mouse glucose-tolerance model

    Thomas et al. reported that survodutide produced a glucose-tolerance area under the curve of 54% relative to vehicle in lean mice.

    Reference [2]

  • Diet-induced obese mouse model

    Thomas et al. reported a 25% reduction in body weight from baseline with survodutide in diet-induced obese mice.

    Reference [2]

06

Verified bibliography

Cited studies by type

The 4 papers this record cites, counted by the kind of work each reports. A count is the size of this record's selection, not of the research that exists, and says nothing about results, safety, effectiveness or approval.

A paper can report more than one kind of work. Each count opens those papers in the bibliography. Compare every record on the Evidence Map.

  1. Reference 1

    BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy.

    Zimmermann T, Thomas L, Baader-Pagler T, Haebel P, Simon E, Reindl W, Bajrami B, Rist W, Uphues I, Drucker DJ, Klein H, Santhanam R, Hamprecht D, Neubauer H, Augustin R

    Molecular metabolism · 2022-11-07 · Journal Article

    current
    PMID 36356832PMC9679702DOI 10.1016/j.molmet.2022.101633SurvodutideGlucagonGLP-1RGCGR

  2. Reference 2

    The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection.

    Thomas L, Martel E, Rist W, Uphues I, Hamprecht D, Neubauer H, Augustin R

    Diabetes, obesity & metabolism · 2024-04-01 · Journal Article

    current
    PMID 38560764DOI 10.1111/dom.15551SurvodutideGLP-1RGCGR

  3. Reference 3

    Structural analysis of the dual agonism at GLP-1R and GCGR.

    Li Y, Zhou Q, Dai A, Zhao F, Chang R, Ying T, Wu B, Yang D, Wang MW, Cong Z

    Proceedings of the National Academy of Sciences of the United States of America · 2023-08-07 · Journal Article

    current
    PMID 37549266PMC10438375DOI 10.1073/pnas.2303696120SurvodutideMazdutideGLP-1RGCGR

  4. Reference 4

    Therapeutic Peptides Targeting PPI in Clinical Development: Overview, Mechanism of Action and Perspectives.

    Cabri W, Cantelmi P, Corbisiero D, Fantoni T, Ferrazzano L, Martelli G, Mattellone A, Tolomelli A

    Frontiers in molecular biosciences · 2021-06-14 · Review

    current
    PMID 34195230PMC8236712DOI 10.3389/fmolb.2021.697586Survodutide

Study models of these references

What kind of experiment each cited paper reports, taken from its abstract unless marked. Not a summary of results.

ReferenceStudy models
Zimmermann T et al. 2022Study models reported: in vitro; animal (mouse, beagle dog) · from the full text
Thomas L et al. 2024Study models reported: in vitro; animal (mouse) · from the abstract
Li Y et al. 2023Study models reported: in vitro · from the abstract
Cabri W et al. 2021Review article

Compare

Record history

Published 2026-09-13.

  • : Sequence and structure
  • : Sequence and structure, References
  • : Sequence and structure

Each entry names the parts of this record that changed on that date. Changes to links between records and to catalogue links are not listed. This history covers the tracked record fields; study findings are not listed here.

Cite this record: Purely Peptides Research Library. Survodutide. Published 2026-09-13; updated 2026-10-15. https://purelypeptides.org/research/compounds/survodutide/

10

Methodology & citation verification

Reference identity is checked against official PubMed metadata. Local deterministic receipts bind each normalized title and canonical metadata record to its verification date. Scientific values remain absent when an authoritative source has not been verified.

Read the full methodology →